Latest News, Press Releases & Events

Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference

-No dose-limiting adverse effects in 14-day multiple ascending dose study -The Company to receive up to total of $5 million to support Phase 2 trial DURHAM, N.C., June 20, 2017 – Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, announced today that Cystic Fibrosis Foundation Therapeutics (CFFT), […]

Continue Reading

Spyryx Biosciences to Present at the 2017 Bio International Convention

DURHAM, N.C., June 16, 2017 - Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, today announced that President and Chief Executive Officer, John Taylor, will present a corporate overview at the 2017 BIO International Convention at the San Diego Convention Center in San Diego, California, on Tuesday, [...]
Continue Reading

Spyryx Biosciences Reports Positive Data on SPX-101 at American Thoracic Society International Conference

Preparations Underway for Launch of Multinational Phase 2 Study DURHAM, N.C., May 23, 2017 – Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, shared positive data highlighting clinical safety and pharmacokinetics in healthy volunteers and the preclinical mechanism of action of SPX-101, the Company’s pipeline therapeutic treatment for […]

Continue Reading